Deuterated psilocybin analog

GSK's phase III GLISTEN trial demonstrates linerixibat significantly improves cholestatic pruritus (relentless itch) in patients with primary biliary cholangitis, addressing a major quality of life concern.

Vanda Pharmaceuticals has submitted a New Drug Application to the FDA for Bysanti (milsaperidone), seeking approval for the treatment of acute bipolar I disorder and schizophrenia.

GH Research's GH001, an inhaled 5-MeO-DMT, met its primary endpoint in a Phase IIb trial for treatment-resistant depression, showing a significant reduction in MADRS scores.

Cybin has launched a Phase 3 clinical trial program, PARADIGM, to evaluate CYB003 as an adjunctive treatment for Major Depressive Disorder (MDD).

Cybin Inc. highlights positive Phase 2 data for CYB003, showing significant efficacy in treating major depressive disorder (MDD).